April 2 (Reuters) - AC Immune SA ACIU.O:
AC IMMUNE SA - ACI-7104.056 IS WELL TOLERATED WITH NO SAFETY ISSUES REPORTED TO DATE
AC IMMUNE REPORTS FURTHER POSITIVE INTERIM RESULTS FROM PHASE 2 TRIAL OF ACI-7104.056 ACTIVE IMMUNOTHERAPY IN EARLY PARKINSON’S DISEASE
Source text: ID:nGNX6K9fwn
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。